PL3449931T3 - Zastosowanie cerebrolizyny - Google Patents

Zastosowanie cerebrolizyny

Info

Publication number
PL3449931T3
PL3449931T3 PL17188180T PL17188180T PL3449931T3 PL 3449931 T3 PL3449931 T3 PL 3449931T3 PL 17188180 T PL17188180 T PL 17188180T PL 17188180 T PL17188180 T PL 17188180T PL 3449931 T3 PL3449931 T3 PL 3449931T3
Authority
PL
Poland
Prior art keywords
cerebrolysin
Prior art date
Application number
PL17188180T
Other languages
English (en)
Polish (pl)
Inventor
Stefan Winter
Herbert Mössler
Original Assignee
Ever Neuro Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ever Neuro Pharma Gmbh filed Critical Ever Neuro Pharma Gmbh
Publication of PL3449931T3 publication Critical patent/PL3449931T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
PL17188180T 2017-08-28 2017-08-28 Zastosowanie cerebrolizyny PL3449931T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17188180.8A EP3449931B1 (en) 2017-08-28 2017-08-28 Use of cerebrolysin

Publications (1)

Publication Number Publication Date
PL3449931T3 true PL3449931T3 (pl) 2020-06-01

Family

ID=59745228

Family Applications (2)

Application Number Title Priority Date Filing Date
PL17188180T PL3449931T3 (pl) 2017-08-28 2017-08-28 Zastosowanie cerebrolizyny
PL18759322T PL3675879T3 (pl) 2017-08-28 2018-08-28 Cerebrolizyna do zastosowania w leczeniu cadasil

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18759322T PL3675879T3 (pl) 2017-08-28 2018-08-28 Cerebrolizyna do zastosowania w leczeniu cadasil

Country Status (15)

Country Link
US (1) US20200376040A1 (enExample)
EP (2) EP3449931B1 (enExample)
JP (1) JP7281450B2 (enExample)
KR (1) KR102676274B1 (enExample)
CN (1) CN111050780B (enExample)
AU (1) AU2018326339A1 (enExample)
CA (1) CA3073991A1 (enExample)
EA (1) EA202090108A1 (enExample)
ES (2) ES2767070T3 (enExample)
HR (1) HRP20200031T1 (enExample)
MX (1) MX2020002267A (enExample)
PH (1) PH12020500376A1 (enExample)
PL (2) PL3449931T3 (enExample)
UA (1) UA129400C2 (enExample)
WO (1) WO2019042983A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220168325A1 (en) * 2019-03-25 2022-06-02 The University Of Vermont Methods to promote cerebral blood flow in the brain
ES2964145T3 (es) 2020-07-13 2024-04-04 Ever Neuro Pharma Gmbh Método para producir un hidrolizado de proteína de cerebro de mamífero
EP4347634A1 (en) * 2021-06-02 2024-04-10 Regeneron Pharmaceuticals, Inc. Treatment of cerebrovascular disease with neurogenic locus notch homolog protein 3 (notch3) agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69126563T2 (de) 1990-04-12 1998-02-05 Ebewe Arzneimittel Verwendung einer Mischung von Peptiden and Aminosäuren für die Prophylaxis oder Behandlung von Dementia
JP2012501967A (ja) 2008-08-20 2012-01-26 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 調節放出型多粒子のホットメルト押出成形

Also Published As

Publication number Publication date
CN111050780A (zh) 2020-04-21
AU2018326339A1 (en) 2020-03-05
KR20200045503A (ko) 2020-05-04
PH12020500376A1 (en) 2020-12-07
JP2020531568A (ja) 2020-11-05
HRP20200031T1 (hr) 2020-03-20
US20200376040A1 (en) 2020-12-03
CN111050780B (zh) 2023-11-03
KR102676274B1 (ko) 2024-06-18
EA202090108A1 (ru) 2020-03-31
EP3449931A1 (en) 2019-03-06
UA129400C2 (uk) 2025-04-16
ES2767070T3 (es) 2020-06-16
WO2019042983A1 (en) 2019-03-07
JP7281450B2 (ja) 2023-05-25
ES2901508T3 (es) 2022-03-22
EP3675879A1 (en) 2020-07-08
EP3675879B1 (en) 2021-09-15
EP3449931B1 (en) 2019-10-16
MX2020002267A (es) 2020-10-22
CA3073991A1 (en) 2019-03-07
PL3675879T3 (pl) 2022-02-14

Similar Documents

Publication Publication Date Title
IL286316A (en) New micro-dystrophins and related method of use
IL274276A (en) CASZ preparations and methods of use
GB2582100B (en) CAS12C Compositions and methods of use
ZA201905677B (en) Glycan-interacting compounds and methods of use
IL258768A (en) Compounds interacting with glycans and methods of use
HUE068842T2 (hu) Vegyületek és alkalmazási eljárásaik
IL282482A (en) Variants of protoxin-II and methods of use
ZA201906169B (en) Synthekine compositions and methods of use
IL269409A (en) Combinations of chk1- and wee1 - inhibitors
PT3661491T (pt) 3-metilmetcatinona para uso no tratamento de um indivíduo sob uma intervenção psicoterapêutica
IL282508A (en) Variants of protoxin-II and methods of use
PT3474822T (pt) Formulações de brincidofovir
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
IL272857A (en) Cofanalisib formulations
ZA201606450B (en) Compounds and their methods of use
PL3449931T3 (pl) Zastosowanie cerebrolizyny
PT3678644T (pt) Formulações de copanlisib
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
SG11202105136WA (en) Application of chidamide
PT3471835T (pt) Utilização de extratos de deschampsia antarctica para combater danos na barreira cutânea humana provocados por agressões ambientais
HK40026040A (en) Use of cerebrolysin
GB201403697D0 (en) Compounds and methods of use
GB201721386D0 (en) Chrondogy of time-wave
GB201810835D0 (en) Methods of use
GB201707716D0 (en) Point of interest location specification